H5N1 avian influenza virus vaccine - Vaxart

Drug Profile

H5N1 avian influenza virus vaccine - Vaxart

Alternative Names: Avian influenza vaccine - Vaxart; Bird flu vaccine - Vaxart; ND1; ND1.1

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxart
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (PO, Capsule)
  • 09 Feb 2016 Vaxart plans a phase II trial for Influenza-A virus H5N1 subtype (Prevention)
  • 01 Nov 2013 Vaxart completes a phase I trial in Influenza virus H5N1 subtype (intestinal delivery) in USA (NCT01698060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top